These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35317527)

  • 1. Distribution of COVID-19 government support and its consequences for firm liquidity and solvency.
    Lalinsky T; Pál R
    Struct Chang Econ Dyn; 2022 Jun; 61():305-335. PubMed ID: 35317527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of COVID-19 on economic recovery: role of potential regulatory responses and corporate liquidity.
    Lin R; Liu X; Liang Y
    Environ Sci Pollut Res Int; 2023 Apr; 30(18):53977-53996. PubMed ID: 36869958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small firms and the COVID-19 insolvency gap.
    Dörr JO; Licht G; Murmann S
    Small Bus Econ (Dordr); 2022; 58(2):887-917. PubMed ID: 38624681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Credit constraints and the severity of COVID-19 impact: Empirical evidence from enterprise surveys.
    Zhang D; Sogn-Grundvåg G
    Econ Anal Policy; 2022 Jun; 74():337-349. PubMed ID: 35281616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-country evidence on the allocation of COVID-19 government subsidies and consequences for productivity.
    Bighelli T; Lalinsky T; Vanhala J
    J Jpn Int Econ; 2023 Jun; 68():101246. PubMed ID: 36710942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lockdown, employment adjustment, and financial frictions.
    Lastauskas P
    Small Bus Econ (Dordr); 2022; 58(2):919-942. PubMed ID: 38624870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of COVID-19 related government response stringency and support policies: Evidence from European firms.
    Janzen B; Radulescu D
    Econ Anal Policy; 2022 Dec; 76():129-145. PubMed ID: 35959486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cui bono? Large-scale evidence on the impact of COVID-19 policy measures on listed firms.
    Haimann M; Kaserer C; Ljubicic K
    Q Rev Econ Finance; 2023 Jun; 89():228-243. PubMed ID: 37132001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SME viability in the COVID-19 recovery.
    McCann F; McGeever N; Yao F
    Small Bus Econ (Dordr); 2023 Jan; ():1-22. PubMed ID: 38625252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are environmentally friendly firms more vulnerable during the COVID-19 pandemic?
    Zhang D; Fang Y
    J Clean Prod; 2022 Jun; 355():131781. PubMed ID: 35466288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19: guaranteed Loans and Zombie Firms.
    Zoller-Rydzek B; Keller F
    CESifo Econ Stud; 2020 Dec; 66(4):322-364. PubMed ID: 34191927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Green management, access to credit, and firms' vulnerability to the COVID-19 crisis.
    Aristei D; Gallo M
    Small Bus Econ (Dordr); 2023 Apr; ():1-33. PubMed ID: 38625207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financing constraints and firm-level responses to the COVID-19 pandemic: International evidence.
    Khan SU
    Res Int Bus Finance; 2022 Jan; 59():101545. PubMed ID: 34580554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zombies, again? The COVID-19 business support programs in Japan.
    Hoshi T; Kawaguchi D; Ueda K
    J Bank Financ; 2023 Feb; 147():106421. PubMed ID: 36568842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supporting SMEs during COVID-19: The case for targeted equity injections.
    Díez FJ; Duval R; Maggi C
    Econ Lett; 2022 Oct; 219():110717. PubMed ID: 35909983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Government policies and firm performance in the COVID-19 pandemic era: a sectoral analysis.
    Turkson D; Addai NB; Chowdhury F; Mohammed F
    SN Bus Econ; 2021; 1(12):168. PubMed ID: 34841266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Firm Exit during the COVID-19 Pandemic: Evidence from Japan.
    Miyakawa D; Oikawa K; Ueda K
    J Jpn Int Econ; 2021 Mar; 59():101118. PubMed ID: 35702632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Firms' participation in the Swiss COVID-19 loan programme.
    Fuhrer LM; Ramelet MA; Tenhofen J
    Swiss J Econ Stat; 2021; 157(1):2. PubMed ID: 33968811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digitalization and resilience during the COVID-19 pandemic.
    Abidi N; El Herradi M; Sakha S
    Telecomm Policy; 2023 May; 47(4):102522. PubMed ID: 37051116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lending relationships and a corporate liquidity shortage: Evidence from the COVID-19 shock in Japan.
    Tsuruta D
    MDE Manage Decis Econ; 2022 Mar; ():. PubMed ID: 35571608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.